Navigation Links
Isis Reports Interim Phase 2 Data on ISIS-APOCIII Rx as a Single Agent in Patients With Very High to Severely High Triglycerides
Date:8/31/2013

nse drug intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents.  ISIS-APOCIIIRx targets apoC-III, a gene produced in the liver that plays a central role in the regulation of serum triglycerides.  Humans who do not produce apoC-III have lower levels of triglycerides and lower instances of cardiovascular disease.  In clinical studies, patients with lower levels of apoC-III and triglycerides exhibit lower cardiovascular event rates.  Humans with elevated levels of apoC-III have increased dyslipidemia associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome.  In addition, the prevalence of type 2 diabetes is increased in patients with elevated triglycerides.Conference Call
At 11:30 a.m. Eastern Time Tuesday, Sept. 3, 2013, Isis will conduct a live webcast and slide presentation conference call to discuss the positive Phase 2 data presented today.  Interested parties may listen to the call by dialing 866-652-5200, or access the webcast with or without audio at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 29 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Ad
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MGC Diagnostics Corporation Reports 2013 Third Quarter Operating Results
2. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
3. Kewaunee Scientific Reports Record Sales and Earnings for First Quarter
4. China Orthopedic Devices Market, Contract Manufacturing in Orthopedic Industry Reports
5. Cancer Diagnostics Market: Sales Forecasts, 2013 Shares & Competitive Strategies Research Reports
6. VirtualScopics Reports Dr. Mostafa Analoui Elected Chairman of the Board
7. China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2014 First Quarter Earnings Results and Schedules Conference Call for August 19, 2013
8. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue and Earnings
9. ULURU Inc. Reports Second Quarter 2013 Financial Results
10. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
11. CorMedix Reports Second Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... announced a strategic collaboration focused on the development, ... active pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s ... their expertise in developing and manufacturing controlled substance ... to tech transfer processes into these facilities. The ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
Breaking Medicine Technology:AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4
... , April 29, 2010 Albireo today,announced ... recent study,assessing the safety, tolerability and efficacy of A3309 ... compound for,the treatment of irritable bowel syndrome with constipation ... during the 2010,Digestive Disease Week (DDW) annual meeting being ...
... SALT LAKE CITY , April 28 Sonic Innovations, ... Administration (VA), is conducting ongoing training events for government clinicians.  The company ... in San Diego, California and April 25 through ... for May 3 through 5 in Salt Lake City, ...
Cached Medicine Technology:Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 2Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 3Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 4Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 5Sonic Innovations Conducts National Training Events for Government Clinicians 2Sonic Innovations Conducts National Training Events for Government Clinicians 3
(Date:9/1/2015)... ... September 01, 2015 , ... The premier online ... has become a leader in podiatric, surgical and wound care conferences . ... place top national speakers at the podium and across the table during hands-on ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... healthcare industry, released their latest predictive use case focused on helping hospital perform ... (HVBP). Under this program, hospital payments are adjusted based on performance across four ...
(Date:8/31/2015)... Beach, FL (PRWEB) , ... August 31, 2015 , ... ... of companies – has teamed up with fellow South Walton property management ... on eliminating extreme poverty in remote parts of the world. The two companies will ...
(Date:8/31/2015)... ... ... The Lisle family law firm of Momkus McCluskey, LLC is pleased ... earn a “Leading Lawyers” distinction. , The “Leading Lawyers” distinction is ... nomination process is based on statewide peer survey nominations and the approval of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about getting ... are interested in learning more about the procedure beyond the information found on the ... recognized hair transplant surgeon Parsa Mohebi will be on hand to answer patients hair ...
Breaking Medicine News(10 mins):Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2
... April 24 /PRNewswire-USNewsire/ -- Showing solid,and surprising, ... president Sen. Barack Obama emerged as the ... week,s annual DTC National,Conference in Washington, D.C. ... advertising, now one of the largest advertising,categories., ...
... WASHINGTON, April 24 Memorial Health, Inc.,parent company ... in Savannah, Ga., has agreed to pay the ... defrauded the federal Medicare,program, the Justice Department announced ... medical center violated,the Medicare self-referral prohibition, commonly known ...
... a birds flight across the sky, the visual experience ... is a complex coordination of neurons that has remained ... in understanding how the brain generates this tracking motion, ... how neurons orchestrate all of the bodys movements. ...
... Peake: Partnership Brings Quality Care Closer to Veterans, ... tower and a,research tower for Denver-area residents and ... Department of Veterans Affairs (VA), the,University of Colorado ... The two structures, to be built on University ...
... with elevated CRP levels play role in metabolic syndrome, ... High levels of C-reactive protein, an inflammatory marker that ... variations in genes that control metabolism, two new studies ... of potential importance for either the treatment of cardiovascular ...
... Latona Life Sciences Inc. (Latona),announced today that ... acquisition,of patent rights and orphan drug status to ... of Juvenile and Adult Rheumatoid,Arthritis., Latona has ... patent,rights to Oralgam with Research Corporation Technologies, Inc., ...
Cached Medicine News:Health News:Pharma Industry Group Favors Obama as Next President 2Health News:Savannah's Memorial Health University Medical Center to Pay U.S. $5.08 Million to Resolve Fraud Allegations 2Health News:Study breaks ground in revealing how neurons generate movement 2Health News:Study breaks ground in revealing how neurons generate movement 3Health News:VA, UCH, UC Denver Partner for New Bed Tower, Expanded Services 2Health News:New Heart Disease Markers Discovered 2Health News:New Heart Disease Markers Discovered 3Health News:New Heart Disease Markers Discovered 4Health News:Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis 2
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: